Top Markets
Coin of the day
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Classement en actions #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Prix de l'action
$4.74
Dernière synchronisation: 2026-08-31
Capitalisation boursière
$372.19M
Changement (1 jour)
-2.47%
Changement (1 an)
-1.04%
Pays
US
Échange Lexeo Therapeutics, Inc. Common Stock (LXEO)

Catégorie

Historique du prix de l'action pour Lexeo Therapeutics, Inc. Common Stock (LXEO)
Prix de clôture le plus élevé : $4.91 le 2026-08-01

Prix de clôture le plus bas : $11.06 le 2023-11-01
Historique du prix de l'action de Lexeo Therapeutics, Inc. Common Stock de 2023 à 2026
Performance annuelle du prix de l'action
Année Performance
2026 (TTM) -31.08%
2025 38.08%
2024 -48.79%
2023 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
$544.38 39.22%
US
$1.03K 45.21%
NL
$121.37 -11.93%
AU
$138.80 476.17%
US
$745.74 4.52%
CH